Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

导出原文传递

翻译打印收藏纠错

作者： Ramanathan, R. K. ^[1] ; Goldstein, D. ^[2] ; Korn, R. L. ^[3] ; Arena, F. ^[4] ; Moore, M. ^[5] ; Siena, S. ^[6] ; Teixeira, L. ^[7] ; Tabernero, J. ^[8] ; Van Laethem, J. -L. ^[9] ; Liu, H. ^[10] ; McGovern, D. ^[11] ; Lu, B. ; Von Hoff, D. D.

作者单位： Scottsdale Med Imaging Ltd, Diagnost Radiol, Scottsdale, AZ USA ^[1] Vall dHebron Univ Hosp, Dept Med Oncol, E-08193 Barcelona, Spain ^[2] Translat Genom Res Inst & Honor Hlth, Clin Res, Scottsdale, AZ USA ^[3] Celgene Corp, Biostat & Res & Design, Summit, NJ USA ^[4] Osped Niguarda Ca Granda, Niguarda Canc Ctr, Dept Hematol & Oncol, Falck Div Oncol, Milan, Italy ^[5] NYU, Langone Arena Oncol, Hematol Oncol, Lake Success, NY USA ^[6] Hop Erasme, Univ Clin Brussels, Brussels, Belgium ^[7] Hop St Antoine, Dept Med Oncol, F-75571 Paris, France ^[8] Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia ^[9] Mayo Clin, Div Hematol Oncol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA ^[10] BC Canc Agcy, Provencial Hlth Serv, Vancouver, BC, Canada ^[11]

关键词 pancreatic cancer positron emission tomography nab-paclitaxel gemcitabine metabolic response

发布时间 2017-04-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交